Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

• Status: Completed
• Trial end date: 2008-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase 1, Multiple Dose Study of MPC-6827 in Subjects with Refractory Solid Tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Myrexis Inc.

Criteria

Inclusion Criteria:

1. Advanced or Metastatic Cancer

2. Measurable / Evaluable Disease

3. Karnofsky score greater than or equal to 70%

4. Adequate Hematology / Organ function

5. No Baseline peripheral or central neuropathy above grade 1

Exclusion Criteria:

1. Hypersensitivity to Cremophor EL

2. Pregnant or Lactating

3. Spinal Cord Compression

4. Pre-existing Dementia / Cognitive Disfunction

5. Require Neupogen or Neulasta to Maintain Neutrophil Count

6. Have Primary Brain Cancer

7. Have history of Ischemic Heart Disease

8. Have Diabetes